Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Adverum Biotechnologies (NASDAQ: ADVM) has granted inducement awards to seven new employees under its 2017 Inducement Plan. The awards include non-qualified stock options to purchase 32,620 shares of common stock at $3.33 per share and restricted stock units (RSUs) for 16,310 shares. The stock options vest over four years with 25% vesting in the first year and the remainder monthly over three years. The RSUs vest over three years, with one-third vesting annually. These grants were approved as inducement material for new employees in accordance with Nasdaq Listing Rule 5635(c)(4).
Adverum Biotechnologies (NASDAQ: ADVM) ha assegnato premi di incentivo a sette nuovi dipendenti nell'ambito del suo Piano di Incentivazione 2017. I premi includono opzioni su azioni non qualificate per l'acquisto di 32.620 azioni ordinarie al prezzo di 3,33 $ per azione e unità di azioni vincolate (RSU) per 16.310 azioni. Le opzioni azionarie maturano in quattro anni, con il 25% che matura nel primo anno e il resto mensilmente nei tre anni successivi. Le RSU maturano in tre anni, con un terzo che matura ogni anno. Questi premi sono stati approvati come incentivi per nuovi dipendenti in conformità alla Regola 5635(c)(4) del Nasdaq.
Adverum Biotechnologies (NASDAQ: ADVM) ha otorgado premios de incentivo a siete nuevos empleados bajo su Plan de Incentivos de 2017. Los premios incluyen opciones sobre acciones no calificadas para comprar 32,620 acciones comunes a $3.33 por acción y unidades de acciones restringidas (RSU) por 16,310 acciones. Las opciones sobre acciones se consolidan en cuatro años, con un 25% consolidado en el primer año y el resto mensualmente durante los siguientes tres años. Las RSU se consolidan en tres años, con un tercio consolidado anualmente. Estas concesiones fueron aprobadas como incentivos para nuevos empleados de acuerdo con la Regla 5635(c)(4) de Nasdaq.
Adverum Biotechnologies (NASDAQ: ADVM)는 2017년 인덕스먼트 플랜에 따라 7명의 신규 직원에게 인센티브 보상을 부여했습니다. 이 보상에는 32,620주의 보통주를 주당 3.33달러에 매수할 수 있는 비자격 스톡옵션과 16,310주의 제한 주식 단위(RSU)가 포함됩니다. 스톡옵션은 4년에 걸쳐 베스팅되며, 첫 해에 25%가 베스팅되고 나머지는 3년 동안 매월 베스팅됩니다. RSU는 3년에 걸쳐 베스팅되며, 매년 3분의 1씩 베스팅됩니다. 이 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 신규 직원 유인을 위해 승인되었습니다.
Adverum Biotechnologies (NASDAQ : ADVM) a accordé des primes d'incitation à sept nouveaux employés dans le cadre de son Plan d'Incitation 2017. Les primes comprennent des options d'achat d'actions non qualifiées pour acquérir 32 620 actions ordinaires au prix de 3,33 $ par action ainsi que des unités d'actions restreintes (RSU) pour 16 310 actions. Les options d'achat d'actions sont acquises sur une période de quatre ans, avec 25 % acquis la première année et le reste mensuellement sur les trois années suivantes. Les RSU sont acquises sur trois ans, avec un tiers acquis chaque année. Ces attributions ont été approuvées comme incitations pour les nouveaux employés conformément à la règle Nasdaq 5635(c)(4).
Adverum Biotechnologies (NASDAQ: ADVM) hat sieben neuen Mitarbeitern im Rahmen seines Inducement-Plans von 2017 Anreizprämien gewährt. Die Prämien umfassen nicht qualifizierte Aktienoptionen zum Kauf von 32.620 Aktien zu je 3,33 $ pro Aktie sowie Restricted Stock Units (RSUs) für 16.310 Aktien. Die Aktienoptionen werden über vier Jahre erworben, wobei 25 % im ersten Jahr und der Rest monatlich über die folgenden drei Jahre vesten. Die RSUs vesten über drei Jahre, wobei ein Drittel jährlich vestet. Diese Zuwendungen wurden als Anreize für neue Mitarbeiter gemäß Nasdaq Listing Rule 5635(c)(4) genehmigt.
- None.
- None.
REDWOOD CITY, Calif., May 02, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 32,620 shares of common stock and restricted stock units (RSUs) for 16,310 shares of common stock to seven new employees under Adverum’s 2017 Inducement Plan. These awards were approved as an inducement material to the new employees entering into employment with Adverum in accordance with Nasdaq Listing Rule 5635(c)(4).
Each stock option has an exercise price of
About Adverum Biotechnologies
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy to preserve sight for life in highly prevalent ocular diseases with the aspirations of developing functional cures to restore vision and prevent blindness. Leveraging the capabilities of its proprietary intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. Additionally, by overcoming the challenges associated with current treatment paradigms for debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe. For more information, please visit www.adverum.com.
Corporate and Investor Inquiries:
Adverum Investor Relations
Email: ir@adverum.com
Media:
Jason Awe, Ph.D.
Executive Director, Corporate Communications
Email: jawe@adverum.com
FAQ
What inducement grants did Adverum Biotechnologies (ADVM) announce on May 2, 2025?
What is the vesting schedule for ADVM's May 2025 inducement stock options?
How do the RSUs vest in Adverum's May 2025 inducement grants?
What was the exercise price for ADVM's May 2025 inducement stock options?
